Merck Reports Strong Q1 Results Driven by Keytruda Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MRK?
Source: Newsfilter
Merck's stock is down 3.02% in pre-market trading, hitting a 20-day low, despite positive market conditions with the Nasdaq-100 and S&P 500 both up.
The company reported strong Q1 results with revenue of $16.3 billion, a 5% increase year-over-year, driven by robust sales of Keytruda, which reached $8.03 billion, exceeding analyst expectations. However, a significant net loss of $4.24 billion was reported, primarily due to a charge from the acquisition of Cidara Therapeutics, which has raised concerns among investors.
Despite the financial loss, Merck's strong performance in oncology and animal health indicates resilience, and the upward revision of its sales outlook suggests potential for future growth, although the stock's current decline reflects market reactions to the acquisition costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 113.150
Low
95.00
Averages
119.53
High
139.00
Current: 113.150
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Salesforce and Merck Collaborate on Unified Customer Platform
- Customer Platform Integration: Salesforce collaborates with Merck Animal Health to build a 360° customer platform using OneCRM, integrating devices, prescriptions, and customer information into a single system, thereby enhancing service convenience and efficiency.
- Enhanced Online Services: The platform is expected to improve Merck Animal Health's online services and customer support, leading to increased customer growth and retention, thereby strengthening market competitiveness.
- Cost and Efficiency Optimization: By leveraging better sales and automation, the system is anticipated to reduce operational costs and improve efficiency, supporting margin growth and enhancing the company's financial health.
- Strategic Collaboration Significance: This partnership not only highlights Salesforce's potential expansion in the healthcare sector but also underscores Merck's commitment to digital transformation, aiming to enhance overall business performance through technological innovation.
See More
Analysts Predict Market Returns for the Next Decade
- Market Return Expectations: Vanguard anticipates average annual returns of only 4% to 5% over the next decade, while Goldman Sachs' Peter Oppenheimer believes U.S. stocks will underperform compared to global markets, highlighting increasing market uncertainty.
- Tobacco Industry Comparison: While Altria Group boasts a forward dividend yield of 5.9%, Philip Morris International's 3.6% yield is backed by stronger performance, particularly with a 15% revenue growth in smoke-free products, indicating a long-term competitive edge.
- Pharmaceutical Industry Challenges: Merck's cancer drug Keytruda will lose patent protections starting in 2028; however, the company expects to generate over $70 billion in annual revenue in the next decade, showcasing the potential of its new product pipeline.
- Uniqueness of Tech Stocks: IBM, a technology company, has raised its dividend for 31 consecutive years with a forward yield of 3%, and its software and consulting services account for 78% of total revenue, providing stable cash flow and dividend support amid economic fluctuations.
See More
Comparative Income Outlook for Philip Morris and Altria
- Income Growth Comparison: While Altria's forward yield stands at 5.9%, Philip Morris's 3.6% yield may be more attractive over the next decade, as its 15% revenue growth in smoke-free product lines demonstrates stronger market adaptability.
- Market Challenge Analysis: Altria faces significant impacts from the smoking cessation movement in the U.S., leading to a slight revenue decline in 2025 primarily due to a 10% drop in cigarette sales volume, which could affect its future dividend growth capacity.
- Patent Risk for Pharmaceuticals: Merck's Keytruda is set to lose some patent protections by 2028; although management anticipates that its new drug portfolio could generate over $70 billion in annual revenue in the next decade, the challenge of replacing Keytruda remains daunting.
- Uniqueness of IBM: International Business Machines (IBM) stands out as a technology stock offering a 3% dividend yield, with its core business model focused on software and consulting services, ensuring stable recurring revenue that is ideal for holding during economic volatility.
See More
Merck Reports Strong Q1 2026 Earnings, Exceeds Expectations
- Significant Revenue Growth: Merck's Q1 2026 revenue reached $16.29 billion, reflecting a 4.9% year-on-year increase that surpassed analyst expectations of $15.82 billion, indicating robust performance in oncology and animal health sectors.
- Improved Adjusted EPS: The company reported an adjusted loss of $1.28 per share, which was 13.2% better than the consensus estimate of $1.47, showcasing management's confidence in new product launches and rising market demand.
- New Product Launches Drive Growth: Merck introduced IDVYNSO for HIV and NUMELVI for canine allergic dermatitis, signaling ongoing efforts to expand its product portfolio and market reach, which are expected to fuel future revenue growth.
- Strategic Investments and Restructuring: Merck plans to increase commercial and R&D spending to support new product launches while reorganizing its commercial operations to enhance execution, with expectations that these initiatives will create long-term value over the next decade.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Analysis of URTH ETF's 52-Week Highs and Lows
- 52-Week Price Range: URTH ETF's low point is $155.05 and high point is $197.88, with the last trade matching the high at $197.88, indicating significant price stability and investor confidence over the past year.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper insights into market trends, aiding in identifying potential buy or sell opportunities to optimize investment strategies.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, allowing for greater flexibility and adaptability to market changes, thus meeting liquidity needs for investors.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF units highlights notable inflows or outflows, with inflows necessitating the purchase of underlying assets and outflows potentially leading to their sale, directly impacting the ETF's component holdings.
See More
Salesforce and Merck Collaborate on Unified Customer Platform
- Customer Platform Integration: Salesforce collaborates with Merck Animal Health to build a 360° customer platform using OneCRM, integrating devices, prescriptions, and customer information into a single system, thereby enhancing service convenience and efficiency.
- Enhanced Online Services: The platform is expected to improve Merck Animal Health's online services and customer support, leading to increased customer growth and retention, thereby strengthening market competitiveness.
- Cost and Efficiency Optimization: By leveraging better sales and automation, the system is anticipated to reduce operational costs and improve efficiency, supporting margin growth and enhancing the company's financial health.
- Strategic Collaboration Significance: This partnership not only highlights Salesforce's potential expansion in the healthcare sector but also underscores Merck's commitment to digital transformation, aiming to enhance overall business performance through technological innovation.
See More
Analysts Predict Market Returns for the Next Decade
- Market Return Expectations: Vanguard anticipates average annual returns of only 4% to 5% over the next decade, while Goldman Sachs' Peter Oppenheimer believes U.S. stocks will underperform compared to global markets, highlighting increasing market uncertainty.
- Tobacco Industry Comparison: While Altria Group boasts a forward dividend yield of 5.9%, Philip Morris International's 3.6% yield is backed by stronger performance, particularly with a 15% revenue growth in smoke-free products, indicating a long-term competitive edge.
- Pharmaceutical Industry Challenges: Merck's cancer drug Keytruda will lose patent protections starting in 2028; however, the company expects to generate over $70 billion in annual revenue in the next decade, showcasing the potential of its new product pipeline.
- Uniqueness of Tech Stocks: IBM, a technology company, has raised its dividend for 31 consecutive years with a forward yield of 3%, and its software and consulting services account for 78% of total revenue, providing stable cash flow and dividend support amid economic fluctuations.
See More
Comparative Income Outlook for Philip Morris and Altria
- Income Growth Comparison: While Altria's forward yield stands at 5.9%, Philip Morris's 3.6% yield may be more attractive over the next decade, as its 15% revenue growth in smoke-free product lines demonstrates stronger market adaptability.
- Market Challenge Analysis: Altria faces significant impacts from the smoking cessation movement in the U.S., leading to a slight revenue decline in 2025 primarily due to a 10% drop in cigarette sales volume, which could affect its future dividend growth capacity.
- Patent Risk for Pharmaceuticals: Merck's Keytruda is set to lose some patent protections by 2028; although management anticipates that its new drug portfolio could generate over $70 billion in annual revenue in the next decade, the challenge of replacing Keytruda remains daunting.
- Uniqueness of IBM: International Business Machines (IBM) stands out as a technology stock offering a 3% dividend yield, with its core business model focused on software and consulting services, ensuring stable recurring revenue that is ideal for holding during economic volatility.
See More
Merck Reports Strong Q1 2026 Earnings, Exceeds Expectations
- Significant Revenue Growth: Merck's Q1 2026 revenue reached $16.29 billion, reflecting a 4.9% year-on-year increase that surpassed analyst expectations of $15.82 billion, indicating robust performance in oncology and animal health sectors.
- Improved Adjusted EPS: The company reported an adjusted loss of $1.28 per share, which was 13.2% better than the consensus estimate of $1.47, showcasing management's confidence in new product launches and rising market demand.
- New Product Launches Drive Growth: Merck introduced IDVYNSO for HIV and NUMELVI for canine allergic dermatitis, signaling ongoing efforts to expand its product portfolio and market reach, which are expected to fuel future revenue growth.
- Strategic Investments and Restructuring: Merck plans to increase commercial and R&D spending to support new product launches while reorganizing its commercial operations to enhance execution, with expectations that these initiatives will create long-term value over the next decade.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Analysis of URTH ETF's 52-Week Highs and Lows
- 52-Week Price Range: URTH ETF's low point is $155.05 and high point is $197.88, with the last trade matching the high at $197.88, indicating significant price stability and investor confidence over the past year.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper insights into market trends, aiding in identifying potential buy or sell opportunities to optimize investment strategies.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, allowing for greater flexibility and adaptability to market changes, thus meeting liquidity needs for investors.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF units highlights notable inflows or outflows, with inflows necessitating the purchase of underlying assets and outflows potentially leading to their sale, directly impacting the ETF's component holdings.
See More
